Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy

BACKGROUND: The recommendations regarding the optimum treatment for advanced non-small-cell lung cancer (NSCLC) patients with wild-type (WT) epidermal growth factor receptor (EGFR) tumors remain unclear. This meta-analysis was conducted to assess the efficacy among programmed death-ligand 1 (PD-L1)/...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Di, Duan, Chongyang, Wu, Fenfang, Chen, Liyong, Chen, Size
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630430/
https://www.ncbi.nlm.nih.gov/pubmed/29029530
http://dx.doi.org/10.18632/oncotarget.20281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630430/
https://www.ncbi.nlm.nih.gov/pubmed/29029530
http://dx.doi.org/10.18632/oncotarget.20281

Ejemplares similares